ReviewEye (London, England)2021
Aggressive posterior retinopathy of prematurity: a review on current understanding.
Review in Eye (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Role of fluorescein angiography guided laser treatment in aggressive retinopathy of prematurity.Eye (London, England) · 2023Trial
- Oxygen therapy-related risk factors for aggressive retinopathy of prematurity in low-risk preterm neonates.Pediatric research · 2026Article
- Current role of aflibercept in retinopathy of prematurity - A review.Indian journal of ophthalmology · 2026Review
- Optimised multivariable prediction model to predict treatment requirement in preterm infants with retinopathy of prematurity.Eye (London, England) · 2026Article
- Zone 3 Aggressive Retinopathy of Prematurity in a Near-Term Delivered Big Baby With a Birth Weight of 3,200 g.Cureus · 2026Article
- The CD39-CD73-adenosine axis: a pivotal regulator of retinal homeostasis and diseases.Frontiers in cell and developmental biology · 2026Review
- Evaluation of aggressive posterior retinopathy of prematurity (AP-ROP) in the German Retina.net ROP registry.Frontiers in medicine · 2026Article
- A case of atypical retinopathy of prematurity with coexisting occlusive vasculitis.American journal of ophthalmology case reports · 2025Article
- Analysis of risk factors for retinopathy of prematurity: a single-center retrospective cohort study.Translational pediatrics · 2025Article
- Article
- Predicting Retinopathy of Prematurity Risk Using Plasma Levels of Insulin-like Growth Factor 1 (IGF1), Tumor Necrosis Factor-Alpha (TNF-Alpha), and Neonatal Parameters.Clinics and practice · 2024Article
- Platelet Counts and Risk of Severe Retinopathy of Prematurity: A Bayesian Model-Averaged Meta-Analysis.Children (Basel, Switzerland) · 2023Review
- Primary and additional treatment preference in aggressive retinopathy of prematurity and type 1 retinopathy of prematurity.BMJ open ophthalmology · 2023Article
- Aggressive Posterior Retinopathy of Prematurity: Long-Term Outcomes Following Intravitreal Bevacizumab.Frontiers in pediatrics · 2022Article
- Analysis of a two-year independent screening effort for retinopathy of prematurity in rural Egypt.BMC ophthalmology · 2021Article
- Aggressive Retinopathy of Prematurity in a Larger and Less Preterm Infant: A Review of Possible Risk Factors.Cureus · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A review of literature was performed, focused on the etiopathogenesis of aggressive posterior retinopathy of prematurity (APROP), the characteristic and atypical clinical features, management strategies, anatomical and visual outcomes. Characteristically APROP has zone I/posterior zone II involvement with prominent plus disease, featureless junction, large vascular loops, flat extra-retinal fibrovascular proliferation, and a rapidly progressive course. The risk factors for APROP are extreme prematurity (birth weight ≤1000 gram and/or gestational age ≤28 weeks), dysregulated oxygen supplementation, intrauterine growth retardation, sepsis, and thrombocytopenia. The uncommon presentations include small zone I disease, a hybrid disease with additional ridge tissue, and APROP in bigger babies with birth weight greater than 1500 g. Laser photocoagulation role is limited by the resultant visual field loss and high refractive error. Although anti-vascular endothelial growth factor injection allows peripheral retinal vascularization; reactivation of disease, systemic absorption of the drug and long-term safety are the chief concerns. Early vitrectomy is required when tractional retinal detachment develops. The visual outcome depends upon the morphology and vascular development of the macula. With the limited yet emerging new understanding of the pathophysiology, a multifaceted rational and individualized treatment strategy is suggested for APROP. Best practices in neonatal intensive care may prevent the occurrence of APROP. Further studies need to be performed for the prevention and safe, effective management of APROP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.